Correlation of Serum Osteocalcin Level and Periodontal Attachment Loss With Osteoporosis Risk Status in Postmenopausal Women

Hutomo, Dimas Ilham; Masulili, Sri Lelyati C.; Tadjoedin, Fatimah Maria; Kusdhany, Lindawati S.

doi:10.22159/ijap.2017.v9s2.22

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Osteoporosis is a systemic metabolic bone disease, which is characterized by decrease of bone mass, as well as degeneration of bone microstructure and is prone to lead to fracture due to increased bone fragility [16]. In Europe, osteoporosis accounts for more disabilityadjusted life years than many non-communicable diseases including rheumatoid arthritis, Parkinson's disease, breast cancer, and prostate cancer [17].…”

Section: Discussionmentioning

confidence: 99%

Pharmacological Treatment of Osteoporosis in Patients With Coronary Heart Disease Complicated by Chronic Heart Failure

Marushchak

Krynytska

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Chronic heart failure (CHF) is a chronic multisystem disorder associated with a myriad of metabolic disturbances. Moreover, CHF may adversely affect bone metabolism and induce a severe bone loss, increasing susceptibility to fractures and osteoporosis. This study investigates the effect of combined calcium with Vitamin D3 supplement called “calcemin advance” and calcitonin in the prophylaxis and treatment of osteopenia and osteoporosis in patients with coronary heart disease (CHD) complicated by CHF with the establishment of their influence on the bone mineral density (BMD).Methods: A total of 59 patients with CHD complicated by CHF. Interventions: The physical examination findings, dual-energy X-ray absorptiometry findings, and treatment results were assessed.Results: The results of the calcemin advance usage in patients with osteopenic changes showed a positive dynamics of the studied parameters, both in the lumbar spine and in the femoral bone. In patients with osteoporosis, the usage of osteoprotective therapy (calcemin advance+miacalcic) contributed to the increasing of BMD in the lumbar spine and in the femoral bone versus patients who received only combined calcium with Vitamin D3 supplement.Conclusions: Our results suggest that bone density screening could be recommended in patients with prevalent CHF. Moreover, the results of our investigation substantiate the necessity and effectiveness of osteoprotective therapy in patients with CHF with osteoporosis by calcitonin (Miacalcic), in combination with combined calcium and Vitamin D3 supplement (calcemin advance), and by only calcemin advance - in patients with CHF and osteopenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacological Treatment of Osteoporosis in Patients With Coronary Heart Disease Complicated by Chronic Heart Failure

Marushchak

Krynytska

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…Osteocalcin, when modified with the help of vitamin K, plays a significant role in binding calcium within bones, thereby contributing to bone strength and density. Osteocalcin is currently regarded as a valid indicator of bone turnover, and its elevation in serum has been observed during specific phases of bone turnover, including osteoporosis, fracture, and repair [ 23 ]. This study is aimed at investigating the effect of systemic administration of omega-3 fatty acids in addition to SRP on clinical periodontal parameters and GCF levels of osteocalcin and AST in menopausal women.…”

Section: Introductionmentioning

confidence: 99%

Nonsurgical Treatment of Periodontitis in Menopausal Patients: A Randomized Control Trial

Eldessouky,

Marie

2024

BioMed Research International

View full text Add to dashboard Cite

Background. Menopause is typically accompanied by significant systemic and oral manifestations, including hormonal changes and increased susceptibility to periodontal disease, which may involve inflammatory biomarkers like aspartate aminotransferase (AST) and osteocalcin in gingival crevicular fluid (GCF). The study is aimed at evaluating the effectiveness of regular inoculation of polyunsaturated fatty acids (PUFAs) as an adjunctive treatment for menopausal women’s periodontitis. Methods. Twenty elderly women with chronic periodontitis were split evenly into two groups by random assignment. Patients in group II (the research group) were given soft gelatin capsules containing PUFAs to be consumed directly once daily for 12 months, as opposed to group I (the control group), who received soft gelatin capsules containing some olive oil (placebo). Scaling and root planning (SRP) were used to address periodontal disease in all cases. Results. At baseline, six and twelve months after treatment, clinical indicators and AST and osteocalcin amounts in the GCF were noted. By the conclusion of the research period, all observed clinical measurements had changed significantly and improved. In addition, there had been a significant decrease in AST levels and a nonsignificant decrease in osteocalcin levels in group II compared to group I. Conclusions. Menopausal women with periodontitis who take omega-3 fatty acid supplements in addition to SRP have better oral health. Significant improvements in clinical indicators and a notable decrease in AST levels within the GCF were observed. However, further research with larger cohorts and extended duration is needed to validate these findings and explain potential mechanisms. This trial is registered with NCT06254118.

show abstract

“…Osteoporosis is a skeletal metabolic disorder characterized by micro-architectural deterioration of bone tissue, this leads to an increase in bone fragility and fracture risk [1]. It is the most common metabolic bone disorder worldwide [2].…”

Section: Introductionmentioning

confidence: 99%

Comparative Study Between Periostin and Osteocalcin as Biomarkers for Osteoporosis and Fracture Risk in Egyptian Postmenopausal Women

Mohamed

Khalifa

Abotaleb

et al. 2020

Int J Pharm Pharm Sci

View full text Add to dashboard Cite

Objective: This study aimed to compare between periostin and osteocalcin as biomarkers in Egyptian postmenopausal women with osteoporosis and to explore their possible relationship with fracture risk. Methods: This study included 90 postmenopausal females recruited from Al-Hussein University Hospital, Cairo, Egypt; divided into three groups; 35 postmenopausal osteoporotic females with low fracture risk (group I), 35 postmenopausal osteoporotic females with high fracture risk (group II), and 20 apparently healthy controls. Serum periostin, osteocalcin, and estrogen were measured by Enzyme Linked Immunosorbent Assay (ELISA). Fracture risk assessment was calculated. Alkaline phosphatase (ALP), total and ionized calcium, Aspartate transaminase (AST), and Alanine transaminase (ALT) were measured spectrophotometrically. Results: The diagnostic performance of periostin for discriminating high fracture risk from low fracture risk groups showed the specificity of (68.6 %) and sensitivity of (100 %), while for osteocalcin the specificity was (51.4 %) and the sensitivity was (68.6 %) respectively. Moreover, the multi Receiver Operating Characteristics (multi-ROC) curve for periostin and osteocalcin together revealed improved specificity and sensitivity of (100 %) each. Conclusion: Periostin was superior to osteocalcin in discriminating high fracture risk from low fracture risk postmenopausal osteoporotic groups. Moreover, dual use of both markers gave the highest discriminative power between low and high fracture risk groups with 100 % specificity and sensitivity.

show abstract

Correlation of Serum Osteocalcin Level and Periodontal Attachment Loss With Osteoporosis Risk Status in Postmenopausal Women

Cited by 3 publications

References 10 publications

Pharmacological Treatment of Osteoporosis in Patients With Coronary Heart Disease Complicated by Chronic Heart Failure

Pharmacological Treatment of Osteoporosis in Patients With Coronary Heart Disease Complicated by Chronic Heart Failure

Nonsurgical Treatment of Periodontitis in Menopausal Patients: A Randomized Control Trial

Comparative Study Between Periostin and Osteocalcin as Biomarkers for Osteoporosis and Fracture Risk in Egyptian Postmenopausal Women

Contact Info

Product

Resources

About